(Q53656759)

English

Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.

scientific article published on 30 December 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients. (English)

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

tumor progression

1 reference

based on heuristic

inferred from title

author name string

Zhitao Wang

1

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

Lulu Zhang

2

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

Huiping Wang

3

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

Shudao Xiong

4

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

Yanli Li

5

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

Qianshan Tao

6

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

Weihua Xiao

7

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

Hui Qin

8

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

Yiping Wang

9

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

Zhimin Zhai

10

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

publication date

30 December 2014

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

64

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

3

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

389-399

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

https://scigraph.springernature.com/pub.10.1007/s00262-014-1646-4

0 references

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Immunodeficiency and immunotherapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Tumor escape mechanism governed by myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Myeloid suppressor cell depletion augments antitumor activity in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Myeloid-derived suppressor cells as regulators of the immune system

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC).

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Immature myeloid cells and cancer-associated immune suppression

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Phenotypic plasticity of MDSC in cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Myeloid derived suppressor cells in human diseases

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

S100A9 a new marker for monocytic human myeloid-derived suppressor cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Myeloid-derived suppressor cells in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

International staging system for multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

History of myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

IL-6 involvement in epithelial cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Regulation of immune responses by TGF-beta

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Regulation of T cell receptor CD3zeta chain expression by L-arginine

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1646-4

21 January 2018

Identifiers

10.1007/S00262-014-1646-4

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25548095

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53656759&oldid=2070820124"